Algorithme Pharma has partnered with Hôpital Maisonneuve-Rosemont (HMR) to offer sponsors increased patient access in key therapeutic areas, including hematology, oncology, nephrology, ophthalmology and metabolic diseases. The HMR clinical research team has more than 60 clinicians and is supported by approximately 75 employees. 
 
“As sponsors look to obtain more information on their lead drug earlier in development, the need to include patient populations in early stage clinical trials continues to increase. Partnering with research teams who have expertise in key therapeutic areas advances our goal of providing a full spectrum of Phase I/IIa clinical research services to our diverse client base,” said Dr. Marc Lefebvre, vice president Scientific & Regulatory Affairs, Algorithme Pharma.
 
Dr. Pierre Dubé, associate director, Clinical Research Division, Hôpital Maisonneuve-Rosemont, added, “In this partnership between private and academic organizations, our clinical investigators and researchers will be able to leverage Algorithme Pharma’s immense wealth of knowledge. For HMR and its Research Centre, this kind of collaboration is part of our strategic objectives which aim to continually deliver innovative treatments to our patients.”